Drugmaker Bayer announced that the Food and Drug Administration has approved a first-of-its-kind drug to treat moderate to severe hot flashes due to menopause.

Lynkuet is a once-daily soft gel capsule that studies show can reduce the frequency and severity of hot flashes. The drug works by blocking both NK1 and NK3 receptors on KNDy neurons, calming the overactive temperature signals that trigger moderate to severe hot flashes.

The drug has already received regulatory approval in Australia, Canada, the United Kingdom and Switzerland, and is pending approval in the European Union.

Bayer expects Lynkuet to be available in the United States next month.

RELATED STORY |

“The FDA approval of Lynkuet is an important new option for women and providers who are treating moderate to severe hot f

See Full Page